Dr. Brink co-founded ConsentSolutions, Inc. in 2006 to further the development of media-based approaches to informed consent for clinical trials. She is the CEO and President. The company grew out of Phase II SBIR NCI funding for the development of an online informed consent process for clinical trials, on which she was the PI. Dr. Brink has authored articles in peer-reviewed publications discussing the effect of media on the patient experience, the need for e-consent, and the pathways to implementation of electronic informed consent in clinical trials.
She has conducted research and reported on patient decision-making processes, and patient knowledge outcomes when using e-consent compared to a paper-based consent.
Dr. Brink has presented on electronic informed consent at DIA, DIACanada, PRIMR, ACRP, NIH and SoCRA, focusing on the benefits for patients, clinical sites and sponsors.
An analytical method is a process. The FDA process validation guidance applies to test methods, like all other processes in the pharmaceutical industry. Therefore, the laboratory or laboratories must demonstrate that a test method performs as intended through the method lifecycle.
Speaker: Susan Brink | View Anytime | Price: ¤144.00 | View DetailsAn analytical method is a process. The FDA process validation guidance applies to test methods, like all other processes in the pharmaceutical industry. Therefore, the laboratory or laboratories must demonstrate that a test method performs as intended through the method lifecycle.
Speaker: Susan Brink | View Anytime | Price: ¤190.00 | View Details